Navigation Links
Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights

BERKELEY HEIGHTS, N.J., May 8 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) today announced financial results for the quarter ended March 31, 2008. From the beginning of the year, the Company has recorded significant milestones including the following:

-- AGENDA Phase 3 trial passes initial DSMB

-- Oral G4544 for bone disease completes single dose-trial in 505(b)(2)


-- Tesetaxel in-licensed -- leading oral taxane and new clinical-stage


-- FDA provides regulatory guidance for Genasense in CLL

-- Company restructures to conserve cash

-- Genta will seek buyer for Ganite and terminates c-myb antisense program

"Genta has successfully diversified with three high-value clinical-stage products in our portfolio," noted Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "The Phase 3 trial of Genasense in melanoma has now enrolled more than 25% of its target, we expect accrual completion this year, and positive results should enable worldwide regulatory filings in 2009. During the quarter, FDA provided substantial guidance on the development of each of our compounds. With G4544, an internally developed compound for skeletal diseases, we have the opportunity to submit a NDA for a product via a streamlined 505(b)(2) regulatory strategy. Our in-licensing of worldwide rights to tesetaxel has provided us with a leading oral taxane that addresses a very large and well-characterized market. This portfolio includes unique compounds that offer significant partnering opportunities to accelerate their development."

Highlights and updates of the Genta programs appear below.

Genasense: The Leading Antisense Drug in Clinical Development

Genasense in Melanoma: Genta is currently enrolling patients with advanced melanoma in a randomized Phase 3 trial of Genasense plus chemotherapy, known as AGENDA. The study is designed to c

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
(Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Madison has long been a home of innovation for entrepreneurs, as ... for them to place their roots. With over 120 technology companies ... growth has led Forbes Magazine to place it first ... ,Every company in Madison has a major project in mind when ...
... Small Times editor discusses nanotech trends at conference , ... week at the University of Wisconsin-Madison, a man with a ... small stuff said Wisconsin is bursting with venture capital ... nanotechnology magazine Small Times , has good reason to ...
... the Wisconsin Technology Network sat down with Tom Still, ... to discuss the basic tenants and initiatives Still and ... grow. This is the first portion of a two-part ... the Wisconsin Technology Council is working to overcome them. ...
Cached Biology Technology:The NeuronFarm works to increase reading comprehension 2The NeuronFarm works to increase reading comprehension 3The NeuronFarm works to increase reading comprehension 4Wisconsin places high in nanotech venture capital, average in innovation 2WTN exclusive interview with Tom Still, Wisconsin Technology Council 2WTN exclusive interview with Tom Still, Wisconsin Technology Council 3WTN exclusive interview with Tom Still, Wisconsin Technology Council 4WTN exclusive interview with Tom Still, Wisconsin Technology Council 5
(Date:4/17/2014)... Yokahama IPCC meeting painted a stark warning on the ... has a greenhouse effect 32 times that of carbon ... that humic substances act as fully regenerable electron acceptors ... held in wetlands instead of being released to the ... is disrupted it may enter into a vicious cycle ...
(Date:4/17/2014)... chock full of wild animals and plant life, but ... are churning away in the soil, decomposing organic matter ... vital role these fungi play in ecological systems, their ... of scientists has generated a genetic map of more ... work was published this week in the Proceedings ...
(Date:4/16/2014)... Nicaragua,s legal, artisanal green sea turtle fishery has uncovered ... turtles in what may have become an unsustainable take, ... and University of Florida. , During the research period, ... were killed between 1991 and 2011, with catch rates ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3
... for sleeping sickness, carried out by the international humanitarian ... research arm, Epicentre, have now been published in the ... sickness affects many tens of thousands of people each ... for which there are few treatment options. The most commonly ...
... are releasing methane, a greenhouse gas, at rates that appear ... acting as a positive feedback to climate warming, said Katey ... , Walter's project is the first time this type of ... estimates were missing a very large and important component of ...
... As part of the international Census of Marine Life ... on an expedition to explore coral reef biodiversity in ... Northwestern Hawaiian Islands Marine National Monument. Led by ... Fisheries Science Center, with funding from NOAA's Coral Reef ...
Cached Biology News:Siberian lakes burp 'time-bomb' greenhouse gas 2First Biodiversity Census of coral reef ecosystems in the NW Hawaiian Islands 2First Biodiversity Census of coral reef ecosystems in the NW Hawaiian Islands 3
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
Biology Products: